SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/330765"
 

Search: onr:"swepub:oai:gup.ub.gu.se/330765" > Type 2 Low Biomarke...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Viinanen, A. (author)

Type 2 Low Biomarker Stability and Exacerbations in Severe Uncontrolled Asthma

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2023

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/330765
  • https://gup.ub.gu.se/publication/330765URI
  • https://doi.org/10.3390/biom13071118DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • We investigated the stability of T2 low status, based on low levels of T2 biomarkers, and exacerbation rates in T2 low and non-T2 low asthma from clinical retrospective data of severe uncontrolled asthma patients. Knowledge of the T2 low biomarker profile is sparse and biomarker stability is uncharted. Secondary care patients with severe uncontrolled asthma and at least two blood eosinophil counts (BEC) and fractional exhaled nitric oxide (FeNO) measured for determination of type 2 inflammation status were evaluated from a follow-up period of 4 years. Patients were stratified into four groups: T2 low(150) (n = 31; BEC < 150 cells/& mu;L and FeNO < 25 ppb), non-T2 low(150) (n = 138; BEC > 150 cells/& mu;L and/or FeNO > 25 ppb), T2 low(300) (n = 66; BEC < 300 cells/& mu;L and FeNO < 25 ppb), and non-T2 low(300) (n = 103; BEC > 300 cells/& mu;L and/or FeNO > 25 ppb). Exacerbation rates requiring hospital care, stability of biomarker status, and cumulative OCS and ICS doses were assessed during follow-up. Among patients with severe uncontrolled asthma, 18% (n = 31) were identified as T2 low(150), and 39% (n = 66) as T2 low(300). In these groups, the low biomarker profile was stable in 55% (n = 11) and 72% (n = 33) of patients with follow-up measures. Exacerbation rates were different between the T2 low and non-T2 low groups: 19.7 [95% CI: 4.3-45.6] in T2 low(150) vs. 8.4 [4.7-13.0] in non-T2 low(150) per 100 patient-years. BEC and FeNO are useful biomarkers in identifying T2 low severe uncontrolled asthma, showing a stable follow-up biomarker profile in up to 72% of patients. Repeated monitoring of these biomarkers is essential in identifying and treating patients with T2 low asthma.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Aakko, J. (author)
  • Lassenius, M. I. (author)
  • Telg, G. (author)
  • Nieminen, K. (author)
  • Kaijala, S. (author)
  • Lehtimaki, L. (author)
  • Kankaanranta, Hannu,1967Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Krefting Research Centre,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition(Swepub:gu)xkankh (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition (creator_code:org_t)

Related titles

  • In:Biomolecules13:72218-273X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view